Yesterday, February 22, 2021, the Ministry of Health of Ukraine registered a vaccine against COVID-19 Oxford/AstraZeneca for emergency use.
The vaccine was developed by the University of Oxford and the British-Swedish company AstraZeneca. The Oxford/AstraZeneca emergency vaccine has already been approved by the World Health Organization and has been approved for use by the United Kingdom, the European Union and India.
The vaccine, Oxford/AstraZeneca, produced at the Serum Institute (India) has a local (trade) name Covishield. Accordingly, the Covishield vaccine, which is arriving in Ukraine today, is officially registered.
Oxford/AstraZeneca (Covishield) applied for registration with the State Expert Center of the Ministry of Health on 15 February. Ukraine has a law that simplifies the procedure for registering COVID-19 vaccines and reduces it to five working days.
Ukraine received information from COVAX on the supply of 2.2 to 3.7 million doses of Oxford/AstraZeneca vaccines in the first and second quarters of 2021. In addition, the vaccine will be purchased at public expense directly from manufacturers.
Ukraine has also entered into additional direct contracts for the supply of the COVID-19 vaccine, which were developed with the participation of AstraZeneca (Britain-Sweden) and NovaVax (USA) and are manufactured at the Serum Institute (India).
On February 21, 2021, Health Minister Maxym Stepanov oversaw the shipment of the first batch of 500,000 AstraZeneca (Covishield) vaccines from a manufacturing plant in Pune, India.
The Oxford/AstraZeneca vaccine is a vaccine on a viral vector platform without the ability to replicate, developed by the University of Oxford and the British-Swedish company AstraZeneca. Two doses of the vaccine with an interval of 28 days are required for complete immunization. Can be stored for up to six months at a temperature of +2 to +8 C.